The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Date and time:
Arya M. Sharma
University of Alberta, Edmonton, Canada
Arya M. Sharma is Emeritus Professor of Medicine and Past-Chair in Obesity Research and Management at the University of Alberta. He is also the Past-Clinical Co-Chair of the Alberta Health Services Obesity Program. Dr. Sharma is founder and Past-Scientific Director of Obesity Canada and co-founder and Past-President of the Canadian Association of Bariatric Physicians and Surgeons. In 2020 he was inducted into the Canadian Academy of Health Sciences.
His past appointments include positions as a Professor of Medicine and Canada Research Chair (Tier 1) at McMaster University (2002-2007), Professor of Medicine at the Franz-Volhard Klinik-Charite, Humboldt University Berlin (2000-2002) and the Free University of Berlin (1994-2000). His interests focus on evidence-based prevention and management of obesity and its complications.
Dr. Sharma is a leading voice in obesity science and medicine, has authored and co-authored more than 500 scientific articles, and has lectured widely on the etiology and management of obesity. He has received several prestigious international and national honours including the 2019 Master of Obesity Medicine Award, the highest distinction awarded by the American Board of Obesity Medicine, the 2014 Scopinaro Lecture, the highest recognition for a non-surgeon by the International Federation of Surgery for Obesity, the 2012 W.L. Asher and Peter Lindner Lecture by the American Society of Bariatric Physicians, as well as a Killam Annual Professorship (2017) and a McLaughlin Gallie Visiting Professorship from the Royal College of Physicians and Surgeons (2014). In 2011 he was awarded an honorary Doctor of Science (DSc) by the University of Guelph-Humber for his contribution to obesity research and advocacy. Dr. Sharma is regularly featured as a medical expert in national and international TV and print media and maintains a widely-read blog at http://www.drsharma.ca
St George Private Hospital Sydney, Sydney, Australia
Dr Rigas is a General Practitioner who has been working in obesity management for over a decade. She is recognised as a National SCOPE Fellow by the World Obesity Federation and was the first Australian GP to be recognised by the Surgical Review Corporation, as a Bariatric Care Specialist.
Dr Rigas is committed to ongoing education in obesity and advocates for equitable access to effective treatments for people living with obesity. She is also on a number of medical advisory and scientific committees on issues of obesity, both nationally and internationally
University of Toronto, Toronto, Canada
Dr Mansoor Husain is Executive Director of the Ted Rogers Centre for Heart Research and Professor of Medicine at the University of Toronto, Canada. He is also an Attending Staff Cardiologist at the Toronto General Hospital and University Health Network.
Dr Husain was the gold medallist in Medicine at the University of Alberta, completed his clinical training at the University of Toronto, Canada, and post-doctoral training in the Program of Excellence in Cardiovascular Biology at the Massachusetts Institute of Technology, USA.
Dr Husain leads an active research program on the molecular bases of cardiovascular diseases such as hypertension, atherosclerosis and heart failure, with a particular emphasis on identifying therapeutic targets involved in pathophysiology. His bench-to-bedside work has improved understanding of the cardiovascular mechanisms of glucagon-like peptide-1 and related anti-diabetic drugs.
University of Liverpool, Liverpool, UK
Professor John Wilding leads clinical research into Obesity, Diabetes and Endocrinology at the University of Liverpool, where he has worked since 1996, after training in Southampton and London. His clinical interests focus on caring for people with diabetes and obesity and he leads specialist services for obesity at Aintree University Hospital – designated a Centre for Obesity Management by the European Association for the Study of Obesity.
John’s research team focusses on developing and evaluating treatments for obesity and diabetes. He has published over 350 papers, chapters and review articles, including clinical trials in diabetes and obesity, as well as studies of adipocyte biology and metabolism.
He chairs the National Clinical Research Network Metabolic and Endocrine Speciality Group. He is an advisor to NICE and NHS England on various aspects of obesity care. He is a past Chair of the UK Association for the Study of Obesity, and immediate past President of the World Obesity Federation.